NSABP FB-7

NERATINIB OR TRASTUZUMAB OR NERATINIB AND TRASTUZUMAB FOLLOWED BY DOXORUBICIN AND CYCLOPHOSPHAMIDE WITH POSTOPERATIVE TRASTUZUMAB IN WOMEN WITH LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER. FB-7 IS A PHASE II, MULTI-CENTER RANDOMIZED STUDY OF NERATINIB IN COMBINATION WITH WEEKLY PACLITAXEL WITH OR WITHOUT TRASTUZUMAB FOLLOWED BY DOXORUBICIN AND CYCLOPHOSPHAMIDE (AC) AS NEOADJUVANT THERAPY FOR WOMEN WITH HER2-POSITIVE LOCALLY ADVANCED BREAST CANCER. PATIENTS IN THE CONTROL ARM WILL RECEIVE NEOADJUVANT TRASTUZUMAB IN COMBINATION WITH WEEKLY PACLITAXEL FOLLOWED BY AC. THE PRIMARY AIM OF THE STUDY IS TO DETERMINE THE PATHOLOGIC COMPLETE RESPONSE (PCR) RATE IN BREAST AND AXILLARY NODES FOLLOWING THE NEOADJUVANT THERAPY REGIMENS. THE SECONDARY AIMS INCLUDE DETERMINATION OF THE PCR RATE IN BREAST ONLY, CLINICAL COMPLETE RESPONSE (CCR) RATE, TWO-YEAR RECURRENCE-FREE INTERVAL, TWO-YEAR OVERALL SURVIVAL, TOXICITY OF THE NEOADJUVANT REGIMENS, AND EXPLORATION OF MOLECULAR AND GENETIC CORRELATES OF RESPONSE.